High-throughput drug screening reveals vulnerabilities to proteasome inhibitors and dinaciclib in clear cell ovarian cancer organoids, highlighting AGR2 as a therapeutic target.
Dose–response curve of carboplatin in six clear cell ovarian cancer organoids CCC, clear cell ovarian cancer
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: